Skip to content

DNA-Tester 23andMe Starts Trial of First Drug Developed In-House

  • Immuno-oncology antibody aimed at treatment of solid tumors
  • Best known for its genetic tests, 23andMe is moving into drugs
Anne Wojcicki
Anne WojcickiPhotographer: David Paul Morris/Bloomberg

DNA-testing giant 23andMe Holding Co. began clinical trials this week of its first drug developed entirely in-house, a critical step toward the company’s ambitions to make and sell its own therapies.

The drug, dubbed 23ME-00610 for now, is an immuno-oncology antibody aimed at treating solid tumors. The first patient in the therapy’s Phase I clinical trials received their first dose this week.